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INTRODUCTION
Helicobacter pylori (H. pylori) is a main etiology
of peptic ulcer, and most studies demonstrate that there
is a strong relationship between H. pylori infection
and gaster lymphoma as well as adenocarcinoma of
gaster body and antrum. Eradication treatment of
H. pylori is strongly assumed that it may reduce
the risk of cancer.1,2,3
Data of clinical studies in Indonesia show that
the prevalence of Helicobacter pylori in patients with
peptic ulcer ranges about 90-100%.4 In patients with
non-ulcer dyspepsia, the prevalence of H. pylori
infection is reported between 20-40% with different
diagnostic methods, i.e. serology, culture and
histopathology.4 Whereas the incidence of H. pylori
in dyspepsia patients who had endoscopic examination
in multicenter studies of 5 big cities in Indonesia
(2003-2004) was 10.2%. A relatively high prevalence
was found in Yogyakarta (30.6%) and the lowest was
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ABSTRACT
The prevalence of Helicobacter pylori in patients with peptic ulcer in Indonesia is very high. It ranges
between 90-100%. In general, patients with gastritis and peptic ulcer usually have dyspepsia symptoms.
The pathophysiology of dyspepsia symptoms caused by Helicobacter pylori has not been clearly
understood. However, it is assumed that the symptoms are correlated to various factors including
inflammation, apoptosis damage, and increased secretion of gastric acid, atrophy and non-atrophy
gastritis as well as the development of peptic ulcer.
The main objective of treatment for Helicobacter pylori infection is elimination of Helicobacter pylori
bacteria. Triple therapy has 80% success rate with no significant adverse events and minimal effect in
inducing resistance to antibiotics. The success rate of eradication treatment in patients with peptic ulcer
is 90%; while an evaluation on improvement of duodenal ulcus following eradication treatment with
one month proton pump inhibitor treatment reveals 90% success rate.
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found in Jakarta (8%).5 This prevalence is lower than
the previous study at M. Djamil hospital in Padang,
which found H. pylori prevalence in patients with
dyspepsia was 60% (serology) and 45%
(histopathology).6 An epidemiology study is being
conducted recently by the Division of
Gastroenterology on the prevalence of H. pylori in
Jakarta. For temporary moment, the study reveals that
the prevalence of H. pylori infection is 52.3% of
310 obtained blood samples 7
H. pylori infection usually causes antral gastritis
which increase acid secretion and the risk of duodenal
ulcer.2 Pan-gastritis may occassionally occur, which
also may increase the acid secretion.3 Some studies
demonstrate that eradication of H. pylori infection
causes various different effect, particularly on
symptoms correlated to the increased acid secretion.
In 1991, the incidence of increased reflux oesophagitis
following the eradication treatment was reported for
the first time. However, next studies reported
different results. Some studies reported improvement
of reflux oesophagitis following the eradication
treatment. However, a different study reported no
improvement.8
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Although there is a strong correlation between
H. pylori infection, chronic gastritis and peptic ulcer,
but the correlation between dyspepsia symptoms and
gastritis induced by H. pylori has not been clearly
demonstrated. It is assumed that the symptoms are
correlated to inflammation, apoptosis damage, increase
gastric acid secretion, atrophy and non-atrophy
gastritis, as well as the development of ulcer.
The success rate of eradication treatment by triple
therapy is about  80-100%, and in a large-scale
randomized study the success rate ranges for 90% of
all patients with peptic ulcer.9 Furthermore, regarding
the correlation between the success rate of
eradication treatment and ulcer recovery, it is reported
that the success rate of primary healing of ulcer after
1 week therapy, which is examined by endoscopy was
80-85%. However, when the PPI treatment was given
for one month period, the success rate of duodenal
ulcer may increase up to 90%.2
The improvement of dyspepsia symptoms in patients
with ulcer ranges for 70 -100%. Goggin et al,
evaluated dyspepsia symptoms as well as other
symptoms correlated to peptic ulcer and they found
improvement rate of such symptoms up to 100%.
The improvement of symptoms was found after
long-term evaluation, with median period of 37 months.10
On the contrary to the response in patients with ulcer,
the response of clinical improvement post-treatment in
patients without ulcer varied and ranges for 2-58%.11
A study by Jaakkimainen et al, reported that there was
a correlation between H. pylori and dyspepsia
symptoms without ulcer and the odd ration was 1.6.
In addition, there was an improvement of symptoms
post-eradication treatment with odd ratio of 1.9.12
However, a study by Harvey et al, reported that there
was no significant result for improvement of heart burn
symptom following two years H. pylori eradication
treatment with odd ratio of 0.99 (CI = 0.88-1.12),
or for the symptoms of gastroesophageal symptom with
odd ratio of 1.04 (CI = 0.91-1.19).8
DYSPEPSIA AND HELICOBACTER PYLORI INFECTION
In general, patients with peptic ulcer and gastritis
usually complain about dyspepsia. Formerly,
dyspepsia was defined as a syndrome of some
gastro-intestinal disease including nausea, vomiting,
bloating, heart burn, belch/a burp, burning sensation,
full sensation at epigastric region and rapid satiation.13
However, by the Rome III criteria in 2006, dyspepsia
is defined as a symptom or symptoms found that
correlated to gastroduodenal disorder, including
epigastric pain, epigastric burning, full sensation or
abdominal discomfort after meal and rapid satiation;
such symptom(s) should be experienced for 3 months
in minimal period of the last 6 months.14
The pathophysiology of dyspepsia symptoms caused
by Helicobacter pylori has not been clearly
understood. However, it is assumed that the symptoms
are correlated to various factors including
inflammation, apoptosis damage, and increased
secretion of gastric acid, atrophy, and non-atrophy
gastritis as well as the development of peptic ulcer.
 H. pylori causes continued gastric inflammation.
First, the inflammation consists of neutrophils
recruitment, followed by lymphocyte T and B, plasma
cell, macrophages, in parallel with epithelial cell
damage. The host response is mainly induced by
bacterial attachment on epithelial cells. The pathogens
may be bound on MHC class II molecules of gastric
epithelial cells and induce apoptosis.4 H. pylori may
cause inflammation at the antrum (antritis) or the body
of gaster (corpusitis) or frequently at both (pangastritis).
In antritis, there are hypergastrinemia, increased acid
production and high risk of duodenal ulcer.
Approximately 2-30% antritis will become duodenal
ulcer.4
Gastritis
In general, the natural history of chronic gastritis
induced by H. pylori infection may be categorized into
non-atrophy chronic gastritis with antrum dominant and
multifocal atrophy gastritis. The characteristics of
non-atrophy chronic gastritis are moderate to severe
inflammation of antrum mucosa; in contrast to mild
inflammation or no inflammation at the stomach body.
There is no atrophy or metaplasia at the antrum.
The patients usually are asymptomatic, but there is
a risk of duodenal ulcer development. Multifocal
atrophy chronic gastritis has specific characteristics,
i.e. inflammation that occurs nearly at all over
the mucosa, which is frequently severe, in the form of
local atrophy or metaplasia on the antrum and
the stomach body. Multifocal atrophy chronic gastritis
is a main risk factor of epithelial gastric dysplasia and
gastric carcinoma.15
Peptic Ulcer
H. pylori that mainly concentrated on the antrum
may cause antrum predominant gastritis, which causes
cell D damage that may secrete somatostatin,
a substance that may inhibit gastrin production. Due to
the cell D damage, somatostatin production decreases
and therefore the gastrin production will increase which
will induce excessive gastric acid production by
the parietal cells. Gastric acid will enter into duodenoum
that may produce increased acidity and causes
duodenitis (active chronic duodenitis), which may lead
to duodenal ulcer.16 Increased acid gastric in
duodenum may cause gastric metaplasia, which may
become the habitation of H. pylori. Moreover, it may
produce acid which will further add duodenal acidity.
Extreme acidity will inhibit mucus and bicarbonate
production which will cause further decrease of
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mucosa invulnerability and favor the development of
duodenal ulcer.17
The development of gastric ulcer induced by
H. pylori infection is different from duodenal ulcer.
H. pylori infection may cause chronic pangastritis
followed by atrophy of mucosa cells at stomach body
and gland, intestinal metaplasia and hypoacidity.
This process is influenced by host factors, the duration
of infection, (location, inflammation response, genetic),
bacterial factors (virulence, bacterial structure,
adhesion, porins, urease enzymes, vacA, cagA, etc);
environment (gastric acid, drugs, NSAID, gall, and other
irritant factor) which finally lead to chronic gastritis
such as gastric ulcer.13
If gastritis induced by H. pylori infection occurs
predominantly in the stomach body, gastric acid
secretion will decrease and the long-term risk of
gastric cancer will be greater. Severe or extensive
inflammation of the stomach body will disturb or inhibit
parietal cells which lead to hypo - or achlorhydria and
it is usually accompanied by mucosa atrophy of
the stomach body, a premalignant lesion for gastric
cancer. In contrast, we assume that the level of
gastric acid secretion, which may be affected by
genetic factors, has a role on different predomination
of gastritis induced by H. pylori infection.
If the secretion of gastric acid is augmented, gastritis
will predominantly occur at antrum. While low
secretion will cause gastritis that occur predominantly
at thestomach body. Both will lead to different illness.4
A study conducted in rodents (mongolian gerbils)
found a significant increase of activity score, gastritis
inflammation and gastrin serum lelvel, and there was
a significant result of reduced gastric acid secretion
6 and 12 weeks after H. pylori inoculation.
We assume that it is mediated by IL-1b, which is
induced by H. pylori.infection.17 The effect of
H. pylori elimination on gastric acid secretion has been
studied by Feldman M et al, that demonstrated
the effect of H. pylori eradication treatment on
the stomach of healthy subjects. The study has
demonstrated that H. pylori elimination treatment may
reduce the gastritis score of stomach body and
antrum, reduce pepsin secretion up to 30%, and inhibit
secretion of non-parietal cells for 35%, without
affecting the secretion of parietal cells.18
EVALUATION FOLLOWING THE HELICOBACTER
PYLORI ERADICATION TREATMENT
The main objective of treatment for H. pylori
infection is elimination of Helicobacter pylori
bacteria.19 Triple therapy has 80% success rate with
no significant adverse events and minimal effect in
inducing resistance to antibiotics. The incidence of
reinfection following eradication treatment is quite low,
i.e. 3.0 - 7.0% in developed countries and 6-14%
in developing countries.1
Evaluation of successful H. pylori eradication
should be conducted in 4 weeks following
the eradication therapy and the best test for evaluation
is by using 13C Urea breath test (UBT). The success
rate of eradication therapy in a large-scale
randomized study is about 90% of all patients. The study
also demonstrated that low-dose triple therapy with
amoxycillin-clarithromycin/nitroimidazole-proton pump
inhibitor treatment was very effective with minimal
adverse effect and it is a standard regimen for
H. pylori eradication treatment.20,21 A study by
Kuipers et al, in patient with H. pylori infection and
clinical manifestation of reflux oesophagitis found 88%
success rate of H. pylori eradication in a group
treated by triple therapy compared to the group treated
by PPI only (24%).22 Wu et al, found 98% success
rate following eradication treatment of triple therapy
in patients with reflux oesophagitis. Moreover, Manes
reported 94% success rate of eradication treatment in
patients with dyspepsia symptom.23,24 Rosengren and
Polson who evaluated eradication treatment in
one month following triple therapy by using 13UBT found
that the success rate of eradication treatment was up
to 100% in patients with duodenal ulcer.25
The effectiveness of dual therapy with amoxycillin
and omeprazole treatment is very low; therefore, such
therapy is not recommended anymore. Koelz et al,
reported H. pylori eradication of 52% and
improvement of dyspepsia symptom by using dual
therapy (amoxicillin and omeprazole) compared to
the control group that used omeprazole only in 6 months
following the eradication treatment with no significant
difference.26 The result is similar to previous study,
i.e. a study by Behrens et al, that demonstrated
different effectiveness of eradication treatment by
using dual therapy compared to triple therapy. They
found 52% eradication by using dual therapy
(omeprazole and amoxicillin) and 83% eradication by
using triple therapy (omeprazole + amoxycillin +
clarithromycin). They also concluded that high-dose
omeprazole treatment did not affect the eradication
result, i.e. there was no significant difference of
eradication result between subjects who had omeprazole
treatment with 1 mg/kgBW/day and 2 mg/kgBW/day
dose.27
As have been proven by various studies, H. pylori
infection may induce progressive change of
inflammation in gastric mucosa, which may lead to
gastric cancer. Mera R et al, who evaluated long-term
cohort study up to 12-years period, found that there is
histopathological improvement in patients who had
H. pylori eradication treatment. Such improvement
was demonstrated by decreased histopathology score.
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The score was 3.77 (95% CI 3.68-3.86) before
treatment and after 6 year treatment, the score was
decrease, i.e. 0.13 lower than previous score, and
12 year following treatment the score was 0.59 lower
compared to previous data.28 The other study also
concluded that there was significant decrease on
activity and inflammation in the antrum and stomach
body (p < 0.001), as well as significant improvement
of atrophy gastritis in the stomach body (p < 0.001)
excluding the antrum.22
The correlation between H. pylori and gastric
cancer has been proven in a lot of studies.  A study by
Helicobacter and cancer collaborative group
reported a relative risk of 5.9 for non-cardiac gastric
cancer incidence in patients with H. pylori. Such risk
is higher than previous meta-analysis study which
reported OR of 2.0-3.1.29 Moreover, regarding
the evaluation of ulcer recovery, it is found that
the success rate of primary healing of ulcer following
one week PPI treatment was 80-85%, after being
examined by endoscopy. However, when the PPI
treatment was given for one month period,
the success rate of duodenal ulcer may increase up to
90%.2 Goggin et al, found 100% recovery rate of
duodenal ulcer in all subjects.10
Improvement of Dyspepsia Symptoms
In patients with dyspepsia, detection on H. pylori
infection is extremely suggested. We recommend UBT
diagnostic test, which is the best non-invasive method.
Manes et al,24 reported a very significant dyspepsia
symptom in patients who had H. pylori detection test
before having treatment. The study compared a group
of patients with dyspepsia symptoms who directly had
PPI and omeprazole treatment (group A) and a group
of patients with dyspepsia symptom who had
H. pylori examination before treatment by using UBT
(group B). In group B, if the H. pylori is negative,
the patients only had omeprazole treatment, while in
patients with positive H. pylori will had eradication
treatment by using triple therapy. The study concluded
a significant difference of dyspepsia symptoms in group
B patients. There was a significant difference of
the patients’ visit in 12 months follow up,
i.e. approximately 231.5 vs. 139.3 with p < 0.001. This
also may reduce the number of patients who should
undergo endoscopy examination, i.e. the patient who
still has dyspepsia symptoms after treatment will have
endoscopy examination for further diagnosis. Hence,
it will reduce treatment cost either by the patients or
government.18 The evaluation of cost effectiveness is
very important because there is a high cost for UBT
examination and eradication treatment. Duggan et al,
reported a relatively high eradication rate (97%) in
patients with H. pylori infection, but the treatment is
quite expensive, i.e. £62.63 for every patient.30
Clinical response following therapy in patients
without ulcer ranges about 2-58%.11 However,
several studies reported different results.
A meta-analysis in patients without ulcer found that
there was 73% improvement of dyspepsia symptoms
following eradication treatment with negative
H. pylori result compared to 45% subjects that
remained positive following the eradication treatment.31
A study by Jaakkimainen et al, reported there was
a correlation between H. pylori and non-ulcer
dyspepsia symptoms with odd ratio of 1.6, and there
was improvement of symptoms following
the eradication treatment with odd ratio of 1.9.11 A study
by Lane et al, in patients with dyspepsia at primary
health care unit concluded that there was only 35%
who still had dyspepsia symptoms following 2 year
H. pylori eradication treatment. However, there was
no different quality of life in patients who had
eradication treatment compared to the placebo.
The other study also reported the number of patient
who should be treated to cure a patient (NNT =
number needed to treat) was 15.32
The effect of H. pylori eradication treatment in
patients with functional dyspepsia is still debated. Talley
NJ evaluated patients with functional dyspepsia who
were infected by H. pylori. Eradication of H. pylori
was found in 85% patients. However, after 12 month
follow up, the improvement of dyspepsia symptoms was
not significantly different between the treatment group
and the control group, i.e. 24% vs. 22%. The study
concluded that there was no valid evidence that
H. pylori eradication will improve functional dyspep-
sia symptoms following 12 months therapy.33
Chiba et al, studied the success rate of H. pylori
eradication treatment and improvement of dyspepsia
symptom in patients with dyspepsia without
differentiating functional and organic dyspepsia. They
found 80% success rate of H. pylori eradication
treatment and 54% improvement of dyspepsia
symptoms. The study found NNT value for a patient
cure of 7.34
Different result in this study may be caused by
different observation period for those patients. Some
investigators assume that there is a different
improvement of dyspepsia symptom in patients
observed after 12 months eradication treatment and
before 12 months eradication treatment. There is higher
incidence of dyspepsia improvement in patients who
are observed more than 12 months. This may be due
to incomplete gastritis recovery following H. pylori
eradication
before 12 months period.28 Goggin et al, evaluated
dyspepsia symptoms as well as other symptoms
correlated to peptic ulcer and found improvement of
such symptoms up to 100%. All subjects showed ulcus
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recovery and disappeared symptoms after long-term
evaluation with median period of 37 months (ranged
26 - 62 months).10 Rosengen & Polson who evaluated
improvement of dyspepsia symptoms in patients with
duodenal ulecer found 88.2% improvement of
dyspepsia symptoms after 1-month therapy. However,
after 4 months therapy, two subjects experienced
dyspepsia symptoms and the other two subjects still
occasionally consumed antacids or anti-H2 receptor
although they did not have any dyspepsia symptom
again. Thus, the percentage of dyspepsia improvement
reduced in the fourth month, i.e. only 76.5%.25
Unlike dyspepsia symptoms, some investigators
observe different correlation between H. pylori and
reflux oesophagitis. Beil et al, conducted a study on
parietal cells of rats. The study demonstrates that from
the isolated parietal cells, H. pylori and MOA
(H. pylori fatty acid cis 9,10-methyleneoctadecanoic)
augments the potency of omeprazole 1.8 times in
inhibiting the acid production but H. pylori do not
affect the potency of omeprazole in inhibiting
the activity of H+/K+-ATPase.35 This study is supported
by Koike et al in Japan which concluded that
the incidence of reflux erosive oesophagitis is more
frequently occur in patients without H. pylori
infection or gaster hyposecretion. H. pylori infection
in reflux oesophagitis case usually occurs without
gaster hyposecretion. Hence, it is assumed that
H. pylori may inhibit the development of reflux
oesophagitis by inducing gastric hypoacidity.36 Some
studies also indicated no significant difference on
clinical improvement of reflux oesophagitis in patients
following eradication treatment. A study by
Harvey et al, reported that there was no significant
result either for heartburn symptom following two year
H. pylori eradication treatment with odd ratio 0.99
(CI = 0.88-1.12), or gastroesophageal reflux with odd
ratio 1.04 (CI = 0.91-1.19).8
Recent epidemiology studies in western countries
tend to demonstrate increased incidence of reflux
oesophagitis (about 25-40%) in accordance with
decreased incidence of duodenal ulcer induced by
H. pylori. This data is also supported by low
prevalence of H. pylori in patients with GERD (about
5-10%), which is assumed to be lower than
the prevalence of H. pylori in control population.37,38
The prevalence of H. pylori in patients with GERD
reported by Raghunath et al, was 38.2% compared to
49.5% in the control group. The estimation value of
OR was 0.59 (CI = 0.51-0.66).38 Although a lot of
studies have demonstrated that there is no correlation
between H. pylori infection and the incidence of
GERD, but in most patients H. pylori eradication does
not induce the development of GERD. A prospective
study indicated GERD recurrent rate of 83% after
one year follow up and there was no significant
different of recurrent rate in patients who had
eradicated H. pylori, persistent H. pylori infection or
patients with negative H. pylori status prior to
the study. 39
H. pylori Treatment in Healthy Population
Although chronic H. pylori infection has been
demonstrated to cause gaster atrophy and intestinal
metaplasia, which are significant risk factors for
the development of gastric cancer, but recent
guidelines do not recommend eradication treatment for
asymptomatic patients. Vaira D et al, examined
169 blood sample donor infected by H. pylori without
dyspepsia symptoms. Upon subjects’ permission,
an eradication treatment was given and after 8 year
follow up the concluded that H. pylori eradication
treatment may inhibit the development of dyspepsia
symptoms, i.e. 83% patients at the end of the trial
remained asymptomatic (147 of 169 patients remained
asymptomatic), and only 13 patients had dyspepsia
symptoms subsequently (i.e. 12 patients with positive
H. pylori status and 1 patient with negative
H. pylori). 40
CONCLUSION
Helicobacter pylori infection is a main etiology of
peptic ulcer incidence and urease test, which is directly
conducted, for specimen biopsy taken by gastroscopy
is a gold standard examination to establish
the diagnosis of H. pylori; while the gold standard
non-invasive examination is urea breath test (UBT).
The success rate of eradication treatment in patients
with peptic ulcer is 90% and the best non-invasive
diagnostic test to evaluate successful eradication
treatment is UBT examination. In addition, evaluation
of ulcer recovery following eradication treatment with
1-month PPI therapy reveals duodenal ulcer recovery
up to 90%.2 In patients without ulcer, the clinical
response ranges about 21-58%. However,
the correlation between improvement of dyspepsia
symptom and successful eradication treatment has not
been clearly demonstrated. Clinical improvement of
dyspepsia symptoms usually occurs in 12 months
following the eradication treatment. There is no
correlation between successful eradication treatment
and clinical improvement of reflux oesophagitis
symptoms.
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